A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management

References

• Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol. 2010;22(4):422–429. doi:10.1016/J.CEB.2010.05.004
   Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459. doi:10.1093/EURHEARTJ/EHX144
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):E1082–E1143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328–350. doi:10.1161/CIRCRESAHA.118.312782
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cellullar Me. 2001;5(4):378–387. doi:10.1111/j.1582-4934.2001.tb00172.x
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022. doi:10.1093/eurheartj/ehv043
   PubMed Web of Science ®Google Scholar
• Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–194. doi:10.1097/JES.0b013e31826c169e
   PubMed Web of Science ®Google Scholar
• Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15(1):58–69.
   PubMed Web of Science ®Google Scholar
• Zimmerman JL, Shen MC. Rhabdomyolysis. Chest. 2013;144(3):1058–1065. doi:10.1378/chest.12-2016
   PubMed Web of Science ®Google Scholar
• Berwanger O, Santucci EV, de Silva PGM, et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA. 2018;319(13):1331–1340. doi:10.1001/JAMA.2018.2444
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2(5):547–555. doi:10.1001/JAMACARDIO.2017.0083
   PubMed Web of Science ®Google Scholar
• Goss GD, Jonker DJ, Laurie SA, et al. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med. 2016;14(1):1–11. doi:10.1186/S12967-016-0836-6
   Web of Science ®Google Scholar
• Haynes R, Jiang L, Hopewell JC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291. doi:10.1093/EURHEARTJ/EHT055
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160–1170.e3. doi:10.1053/j.gastro.2016.01.004
   PubMed Web of Science ®Google Scholar
• Wierzbicki A, Lumb PJ, Chik G. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 2001;55(10):673–675.
   Web of Science ®Google Scholar
• Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31–41. doi:10.1016/S2468-1253(19)30320-6
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445. doi:10.1001/JAMA.294.19.2437
   PubMed Web of Science ®Google Scholar
• Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007;107(4):433–443. doi:10.1159/000100908
   PubMed Web of Science ®Google Scholar
• Drobný M, Pullmann R, Odalos I, Skerenova M, Sániova B. Incidence of skeletal muscle disorders after statins’ treatment: consequences in clinical and EMG picture. Neuroendocrinol Lett. 2014;35(2):123–128.
   Web of Science ®Google Scholar
• Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 2010;106(11):1594–1601. doi:10.1016/j.amjcard.2010.07.041
   Web of Science ®Google Scholar
• Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7(2):102–108. doi:10.1016/j.jacl.2012.06.006
   PubMed Web of Science ®Google Scholar
• Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther. 2010;90(10):1530–1542. doi:10.2522/PTJ.20090251
   PubMed Web of Science ®Google Scholar
• Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2016;33(2):246–257. doi:10.1080/01926230590908213
   Web of Science ®Google Scholar
• Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66(2):124–132. doi:10.3138/ptc.2012-65
   PubMed Web of Science ®Google Scholar
• Tanaka S, Sakamoto K, Yamamoto M, et al. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J Pharmacol Sci. 2010;114(4):454–463. doi:10.1254/JPHS.10229FP
   Web of Science ®Google Scholar
• Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J. 2007;21(14):4087–4094. doi:10.1096/FJ.07-8713COM
   Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105. doi:10.1016/J.PHARMTHERA.2006.03.003
   PubMed Web of Science ®Google Scholar
• Knauer MJ, Urquhart BL, Schwabedissen HEM, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106(2):297–306. doi:10.1161/CIRCRESAHA.109.203596
   PubMed Web of Science ®Google Scholar
• Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288–295. doi:10.1345/aph.1A289
   PubMed Web of Science ®Google Scholar
• Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Rep. 2018;2018(3):86–88. doi:10.1093/OMCR/OMX104
   Web of Science ®Google Scholar
• Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21(5):494–506. doi:10.1002/pds.3199
   Web of Science ®Google Scholar
• Yang BR, Seong JM, Choi NK, et al. Co-medication of statins with contraindicated drugs. PLoS One. 2015;10(5):1–11. doi:10.1371/journal.pone.0125180
   Web of Science ®Google Scholar
• Danis R, Akbulut S, Ozmen S, Arikan S. Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case Rep Med. 2010;2010:2–5. doi:10.1155/2010/537818
   Google Scholar
• Wang D, Wang Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism. Med US. 2018;97(14):1–3. doi:10.1097/MD.0000000000010318
   Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):E38–E81. doi:10.1161/ATV.0000000000000073
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435. doi:10.1056/NEJMoa050461
   PubMed Web of Science ®Google Scholar
• Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352–358. doi:10.1002/pds.1287
   PubMed Web of Science ®Google Scholar
• Unnikrishnan D, Satish B. Exertion-induced rhabdomyolysis in a patient on statin therapy. Nephrol Dial Transplant. 2005;20(1):244–247. doi:10.1093/ndt/gfh578
   Web of Science ®Google Scholar
• Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci. 2005;88(2):551–561. doi:10.1093/toxsci/kfi305
   Web of Science ®Google Scholar
• Lenz TL, Lenz NJ, Faulkner MA. Potential interactions between exercise and drug therapy. Sports Med. 2004;34(5):293–306. doi:10.2165/00007256-200434050-00002
   Web of Science ®Google Scholar
• Tietze DC, Borchers J. exertional rhabdomyolysis in the athlete: a clinical review. Sports Health. 2014;6(4):336–339. doi:10.1177/1941738114523544
   PubMedGoogle Scholar
• Yoshizawa T, Omori K, Takeuchi I, et al. Heat stroke with bimodal rhabdomyolysis: a case report and review of the literature. J Intensive Care. 2016;4(1):1–5. doi:10.1186/s40560-016-0193-9
   Google Scholar
• NIOSH. Prevention: rhabdomyolysis | NIOSH | CDC; 2019. Available from: https://www.cdc.gov/niosh/topics/rhabdo/prevention.html. Accessed July 14, 2021.
   Google Scholar
• Food and Drug Administration. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury | FDA; 2021. Available fromhttps://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor. Accessed July 11, 2021.
   Google Scholar
• Khalilieh S, Yee KL, Sanchez RI, et al. Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother. 2017;61(2):e01364–16. doi:10.1128/AAC.01364-16
   PubMed Web of Science ®Google Scholar
• Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: a practical approach for pharmacists. Can Pharm J. 2018;151(3):179–188. doi:10.1177/1715163518768534
   Web of Science ®Google Scholar
• Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–564. doi:10.1001/ARCHINTE.163.5.553
   PubMedGoogle Scholar
• Koba S, Inoue I, Cyrille M, et al. Evolocumab vs. ezetimibe in statin-intolerant hyperlipidemic Japanese patients: phase 3 GAUSS-4 trial. J Atheroscler Thromb. 2020;27(5):471–484. doi:10.5551/JAT.50963
   Web of Science ®Google Scholar